XOMA Share Price

Open 5.34 Change Price %
High 5.55 1 Day 0.20 3.74
Low 5.34 1 Week -0.26 -4.48
Close 5.55 1 Month 0.18 3.35
Volume 23274 1 Year 4.19 308.09
52 Week High 7.62
52 Week Low 0.00
XOMA Important Levels
Resistance 2 5.74
Resistance 1 5.66
Pivot 5.48
Support 1 5.44
Support 2 5.36
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

XOMA Corporation (NASDAQ: XOMA)

XOMA Technical Analysis 3
As on 5th Dec 2016 XOMA Share Price closed @ 5.55 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.46 & Buy for SHORT-TERM with Stoploss of 3.80 we also expect STOCK to react on Following IMPORTANT LEVELS.
XOMA Target for December
1st Target up-side 6.93
2nd Target up-side 7.87
3rd Target up-side 8.81
1st Target down-side 4.23
2nd Target down-side 3.29
3rd Target down-side 2.35
XOMA Other Details
Segment EQ
Market Capital 188892816.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.xoma.com
XOMA Address
XOMA
2910 Seventh Street
Berkeley, CA 94710
United States
Phone: 510-204-7200
Interactive Technical Analysis Chart XOMA Corporation ( XOMA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on XOMA Corporation
XOMA Business Profile
XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company�s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company�s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement. On January 17, 2012, it announced that it had acquired certain the United States rights to a portfolio of antihypertensive products from Servier. The portfolio includes ACEON (perindopril erbumine), a marketed angiotensin converting enzyme (ACE) inhibitor, and three fixed-dose combination (FDC) product candidates where a form of perindopril (perindopril arginine) is combined with another active ingredient.